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RYGB rapidly reverses diabetes.
Ramracheya et al. demonstrate that
RYGB normalizes glycaemia in diabetes
by restoring insulin and glucagon
secretion. They show that the gut
hormone PYY mediates these
improvements and that it restores
secretory function in diabetic islets.
These findings suggest that PYYmight be
a T2D therapeutic target.
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Roux-en-Y gastric bypass (RYGB) is a weight-reduc-
tion procedure resulting in rapid resolution of type 2
diabetes (T2D). The role of pancreatic islet function in
this restoration of normoglycemia has not been fully
elucidated. Using the diabetic Goto-Kakizaki (GK) rat
model, we demonstrate that RYGB restores normal
glucose regulation of glucagon and insulin secretion
and normalizes islet morphology. Culture of isolated
islets with serum from RYGB animals mimicked
these effects, implicating a humoral factor. These
latter effects were reversed following neutralization
of the gut hormone peptide tyrosine tyrosine (PYY)
but persisted in the presence of a glucagon-like pep-
tide-1 (GLP-1) receptor antagonist. The effects of
RYGB on secretion were replicated by chronic expo-
sure of diabetic rat islets to PYY in vitro. These find-
ings indicate that the mechanism underlying T2D
remission may be mediated by PYY and suggest
that drugs promoting PYY release or action may
restore pancreatic islet function in T2D.
INTRODUCTION
Roux-en-Y gastric bypass (RYGB) is the most common form of
weight loss surgery. Although developed originally as a weight-
reduction therapy, RYGB can lead to full and durable remission
of type 2 diabetes (T2D) in up to 90% of cases (Buchwald
et al., 2004). The remission occurs within days of surgery and
before any significant weight loss. The mechanisms behind this
improvement remain unknown.
Human T2D is characterized by dysfunction of both glucose-
stimulated insulin secretion (GSIS) from pancreatic b cells and
inappropriate regulation of glucagon production from a cells
(Unger and Cherrington, 2012). The importance of glucagon in
diabetes is confirmed by the finding that mice lacking glucagon
receptors remain normoglycemic even after complete destruc-
tion of b cells (Lee et al., 2012).944 Cell Reports 15, 944–950, May 3, 2016 ª 2016 The Authors
This is an open access article under the CC BY license (http://creativeAlthough pancreatic islets are center stage in diabetes,
the impact of RYGB on islet function, especially on glucagon
secretion, has not been fully elucidated. Elevated levels of
the incretin hormone GLP-1 were initially thought to trigger
improved glucose homeostasis and remission of diabetes
upon surgery. However, the beneficial effects of surgery persist
in rodents lacking both GLP-1 and its receptor, suggesting a
GLP-1-independent mechanism (Mokadem et al., 2014; Ye
et al., 2014).
Using a diabetic rat model of RYGB, we have investigated
the effects of surgery on islet function and the underlying
mechanisms.
RESULTS
RYGB Restores Impaired Islet Secretory Properties and
Improves Metabolic Parameters
Both insulin and glucagon secretion was assessed in islets
isolated from spontaneously diabetic Goto-Kakizaki (GK) rats
post-RYGB surgery. Islets from the sham-operated diabetic
group displayed reduced GSIS and lack of glucose-induced
suppression of glucagon release, which was stimulated rather
than inhibited at 20 mM glucose (Figures 1A and 1B). These
abnormalities are strikingly similar to those observed in islets
from T2D patients (Zhang et al., 2013).
RYGB surgery resulted in marked improvement of GSIS
compared to the sham operation (the response at 6 and 20 mM
glucose increased1.4-foldand12.7-fold, respectively) (Figure1A).
Glucagon suppression was restored at 6 and 20 mM glucose in
the RYGB group (Figure 1B), and the inverted glucose response
observed at 20 mM glucose in the sham group was corrected.
In addition, there was a significant increase in insulin (RYGB
versus sham, 13.1 ± 1.0 versus 6.9 ± 0.8 ng/islet; mean ± SEM)
and glucagon content (RYGB versus sham, 894.2 ± 37.6 versus
630.2 ± 69.7 pg/islet) in the RYGB group. RYGB animals lost
8% of their body weight compared to 1% in the sham-operated
group (Figure S1A). This was associated with a modest reduction
in calorie intake (Figure S1B), a significant decrease in plasma
glucose levels (Figure S1C), and a 4-fold drop in water consump-
tion in the RYGB animals (Figure S1D), consistent with remission
of diabetes.commons.org/licenses/by/4.0/).
Figure 1. Islet Secretion and Morphology
Are Improved in GK Rats Post-RYGB
(A and B) Insulin (A) and glucagon (B) secretion in
islets isolated from sham (black bars) or RYGB
(gray bars) animals. Secretion is presented as
percentage of that secreted at basal (mean ± SEM
as percentage of total islet content; insulin: sham,
0.023 ± 0.004; RYGB, 0.046 ± 0.001; glucagon:
sham, 0.216 ± 0.053; RYGB, 1.314 ± 0.025; n = 6–
12 rats; two to five experiments). yp < 0.05, yyp <
0.01 versus 1 mM glucose, #p < 0.05 for indicated
comparisons.
(C–H) Pancreatic sections from Wistar (C and F),
GK control (D and G), and GK RYGB (E and H)
animals, stained for glucagon (C–E) and insulin
(F–H). Scale bar represents 100 mM.
(I) Shape factor analysis, used as ameasure of islet
structure, was determined in GK controls (n = 4),
Wistar (n = 3), and RYGB-operated animals (n = 3).
(J) Insulin positive area/total islet area was as-
sessed in these animals (n > 30 islets/animal). Data
are presented as mean ± SEM, **p < 0.01, ***p <
0.001 compared to Wistar controls, #p < 0.05 for
indicated comparisons.
See also Figures S1 and S2.RYGB Influences Islet Gene Transcription
The effects of RYGB on islet secretion correlated with changes
in gene expression levels. Expression of insulin, glucagon, and
somatostatin genes were elevated 5-, 3-, and 9-fold, respec-
tively, in the RYGB group compared to sham animals (Fig-
ure S2A). Moreover, expression of Pdx1 and Nkx6.1, two key
transcription factors regulating b cell development and identity
(Cerf, 2006), were elevated 3- and 4-fold, respectively.
RYGB Restores Islet Morphology
Whereas islets from non-diabetic Wistar rats are largely sphe-
roidal (Figures 1C and 1F), GK rat islets exhibit a ‘‘starfish’’
appearance (Ho¨o¨g et al., 1997) (Figures 1D and 1G). Following
RYGB, islet morphology was restored to that of non-diabetic is-
lets (Figures 1E and 1H). Themorphological changes were quan-
tified by islet shape factor measurements (Figure 1I). Analyses of
immuno-labeled sections demonstrated that the proportion of
insulin-positive cells/islet was lower in the sham-operated group
compared to RYGB rats. Insulin-positive cell proportions were
significantly higher following RYGB (Figure 1J) and the intra-islet
localization of the glucagon-positive a cells was similar to that
seen in non-diabetic islets (compare Figures 1C and 1E). Therewas no change in the a cell area propor-
tion (Figure S2B). Islet density/pancreas
was lower in diabetic rats, a factor that
was not corrected by RYGB (Figure S2C).
Effects of RYGB on Islet Function
Are Modulated by a Humoral Factor
To determine whether the effects of
RYGB on pancreatic islet function was
related to a blood-borne factor, rat islets
were pretreated for 48 hr with sera ob-tained from sham or RYGB rats. Whereas islets treated with
sham serum exhibited only a 2-fold increase in GSIS, islets
exposed to serum from RYGB animals displayed a 14-fold stim-
ulation (Figure 2A). Glucagon suppression at 6 and 20 mM
glucose was significantly improved by treatment with RYGB
serum (Figure 2B). Insulin and glucagon content were signifi-
cantly higher in the RYGB serum-treated group compared to
the sham serum group (Figures S3A and S3B).
Effects of RYGB Are Not Mediated by GLP-1
Increased post-prandial GLP-1 levels have been implicated as
the causal factor for improved glucose homeostasis and remis-
sion of diabetes following RYGB (Lindqvist et al., 2013), but it
is notable that the beneficial effects of surgery persist in mice
lacking GLP-1 and its receptor (Mokadem et al., 2014; Ye
et al., 2014). We investigated the involvement of GLP-1 in the
RYGB GK rat model. Enhanced GSIS in islets from RYGB ani-
mals persisted in the presence of the GLP-1 receptor antagonist
exendin (9–39), excluding a role for locally released GLP-1 as a
mediator of improved islet function (Marchetti et al., 2012) (Fig-
ure S3C). To assess further the possible involvement of systemic
GLP-1, plasma levels of the incretin were determined underCell Reports 15, 944–950, May 3, 2016 945
Figure 2. Metabolic Benefits of RYGB Are Driven by a Humoral Factor
(A and B) Insulin (A) and glucagon (B) secretion from rat islets treated for 48 hr with serum from sham- (black) or RYGB-operated (gray bars) animals. Data are
presented as percentage of basal secretion (mean ± SEM as percentage of content; insulin: sham, 0.974 ± 0.064; RYGB, 2.274 ± 0.0749; glucagon: sham,
0.748 ± 0.032; RYGB, 5.251 ± 0.947; n = 8 rats, five or six experiments). *p < 0.05, **p < 0.01 versus 1 mM glucose sham, yyp < 0.01 versus 1mM glucose RYGB,
#p < 0.05 for indicated comparisons.
See also Figure S3.basal conditions. No significant change in total GLP-1 levels was
noted in the RYGB rat serum at 10–14 days or 8 months post-
surgery (Figure 3A). Co-application of exendin (9–39) to rat islets
pre-cultured with RYGB serum also failed to suppress enhanced
GSIS responses (Figure S3D).
Increased PYY Levels Post-RYGB
Another hormone co-secreted by the L-cells in response to
glucose intake is peptide tyrosine tyrosine (PYY) (Adrian et al.,
1985). Circulating PYY levels are drastically reduced in obesity
and T2D (Batterham et al., 2003). In the RYGB rat model, total
plasma PYY concentrations were markedly higher within 10–
14 days following surgery compared to the sham group and
remained significantly elevated for up to 8 months (Figure 3B).
Effects of PYY on Islet Secretory Function
Despite an established role of PYY in metabolism, there is a lack
of consensus on its role on insulin secretion (Persaud and Be-
wick, 2014). Moreover, the effect of PYY on glucagon release
is unknown. Short-term (1 hr) exposure of rat isolated islets to
exogenous PYY did not affect GSIS (Figure S4). To replicate
the sustained elevation of PYY seen in vivo, long-term effects
of the peptide were studied at a physiological concentration of
100 pM and a higher concentration of 100 nM in vitro using a
chronic (48–60 hr) culture protocol. Compared to uncultured
islets, this culture protocol is associated with reduced GSIS
and loss of glucose-induced suppression of glucagon release.
However, treatment with both low and high PYY concentrations
resulted in a dramatic improvement of GSIS (Figure 3C) and
restoration of glucose-induced inhibition of glucagon secretion
(Figure 3D). PYY acts via neuropeptide Y (NPY) family of recep-
tors, of which Npy1r is expressed abundantly in islets at the
transcript (Persaud and Bewick, 2014) and protein levels
(L.J.M., unpublished data). Inhibition of Npy1r using the antago-
nist BIBP-3226 resulted in complete reversal of the restorative ef-
fects of long-term PYY exposure onGSIS (Figure 3E). Application
of the antagonist on its own had no effect on GSIS (Figure S4B).946 Cell Reports 15, 944–950, May 3, 2016Effects of RYGB Are Mediated by PYY
To test whether PYY is the humoral mediator underlying the
beneficial effects of RYGB on islet function, healthy rat islets
were exposed to serum from RYGB rats in the absence or pres-
ence of a PYY-specific antibody at a concentration known to
react with the peptide. Immuno-neutralization of PYY attenuated
the effects of the serum resulting in a 75% lower response to
GSIS compared to that in the absence of the antibody (Figure 3F).
The specificity of the antibody was confirmed by pre-incubation
of islets with the synthetic peptide, resulting in a lack of immuno-
histochemical detection of PYY (Figure S4B). When serum from
sham-operated rats was supplemented with PYY, it reproduced
the beneficial effects of RYGB on islet secretion (Figures 3G and
3H). These effects were reversed by immuno-neutralization of
exogenous PYY (Figures 3G and 3H). It is of note that, in contrast
to the effects of PYY in the supplemented sham serum, immuno-
neutralization failed to fully reverse the effects of RYGB serum
(Figure 3F), probably implicating the existence of additional
factor(s).
PYY Restores Impaired Islet Secretion in Diabetes
PYY infusion in diabetic rats lowers body weight and HbA1c
levels (Pittner et al., 2004), but its impact on impaired islet
function remains unknown. We tested the effects of PYY directly
on islets isolated from severely diabetic GK rats (plasma
glucose: 26 ± 2 mM). These islets exhibited impaired glucose-
mediated insulin and glucagon secretion (Figures 4A and 4B).
However, following treatment with PYY for 48–60 hr, GSIS was
restored (Figure 4A) and glucose-induced inhibition of glucagon
secretion was normalized (Figure 4B). The changes in islet hor-
mone release were associated with a 1.5-fold increase in Pdx1
gene expression level (Figure 4C), consistent with the effect of
RYGB (Figure S2C).
PYY Is Effective in Human Islets
Finally, we confirmed that PYY is also effective in human
islets. Following chronic treatment with both low and high
Figure 3. PYYMediates the Effects of RYGB
(A and B) Total plasma GLP-1 (A) and PYY (B)
levels in GK sham-operated and RYGB animals at
10–14 days and 8 months post-surgery.
(C and D) Insulin (C) and glucagon (D) secretion
from rat islets chronically cultured with 100 pM
PYY (gray), 100 nM PYY (white), or in the absence
of PYY (black bars). Data are presented as per-
centage of basal secretion (mean ± SEM as per-
centage of content; insulin: 100 pM PYY: 0.1 ±
0.004; 100 nM PYY: 0.137 ± 0.016; control alone:
0.133 ± 0.014; glucagon: 100 pM PYY: 2.731 ±
0.211; 100 nM PYY: 2.287 ± 0.0.185; control alone:
1.196 ± 0.368; n = 6–8 rats; 3–11 experiments).
*p < 0.05 versus 1 mM glucose control, yp < 0.05
versus 1 mM glucose with 100 pM PYY, ǂǂǂp <
0.001 versus 1mMglucosewith 100 nMPYY, ##p <
0.01, ###p < 0.001 for indicated comparisons.
(E) Insulin secretion from rat islets chronically
cultured with PYY in the presence (gray) or
absence (black) of the NPY1R antagonist BIBP-
3226 (1 mM). Data are presented as percentage of
basal secretion (mean ± SEM as % of content;
PYY: 0.062 ± 0.013; PYY+BIBP-3226: 0.178 ±
0.061; n = 6 experiments). *p < 0.05 versus 1 mM
glucose control, #p < 0.05 for indicated com-
parison.
(F) Insulin secretion from rat islets at 1 mM (black)
and 20 mM (gray bars) glucose following chronic
exposure to RYGB serum, with or without PYY
antibody (1/500). Data are presented as per-
centage of basal secretion (mean ± SEM as % of
content; serum alone: 0.223 ± 0.018; with anti-
body: 0.253 ± 0.03; n = 6 experiments). *p < 0.05,
**p < 0.01 versus 1 mM glucose.
(G and H) Insulin (G) and glucagon (H) secretion
from rat islets following chronic exposure to sham-
operated serum supplemented with 100 nM PYY
with (white) or without (gray) PYY antibody (1/500)
or sham-operated serum alone (black). Data
are presented as percentage of basal secretion
(mean ± SEM as % of content; insulin: PYY with
antibody: 0.009 ± 0.001; PYY without antibody:
0.006 ± 0.0002; sham serum alone: 0.974 ± 0.064;
glucagon: PYY with antibody: 0.472 ± 0.026; PYY
without antibody: 1.109 ± 0.0.161; sham serum alone: 0.748 ± 0.032; n = 6–8 rats; six experiments). *p < 0.05, **p < 0.01 versus 1 mM glucose sham serum,
yp < 0.05, yyyp < 0.001 versus 1 mM glucose sham serum with PYY, ǂp < 0.05 versus 1 mM glucose sham serum, PYY and anti-PYY. #p < 0.05, ##p < 0.01, ###p <
0.001 for indicated comparisons.
See also Figures S3 and S4.concentrations of PYY, insulin secretionwas enhanced at 20mM
glucose (Figure 4D). Glucose-induced glucagon suppression
was also significantly improved in PYY-treated islets (Figure 4E).
DISCUSSION
RYGB surgery leads to rapid resolution of T2D but the mecha-
nisms involved remain elusive. It is commonly believed that
improved islet function underlies the beneficial effects, but
mechanistic studies are still missing.
Although increased post-prandial GLP-1 secretion following
RYGB surgery has been reported (Salehi et al., 2011; Shin
et al., 2010), no changes in fasting GLP-1 levels in RYGB-oper-
ated patients have been documented (Clements et al., 2004;Pournaras et al., 2010). Moreover, there is evidence demon-
strating that central or peripheral GLP-1 receptor signaling is
not critical for the beneficial effects of RYGB. Thus, the role of
GLP-1 as a mediator of surgery-associated benefits remains
inconclusive. In our study, total GLP-1 levels following RYGB
were unchanged in plasma taken under ad libitum feeding
conditions.
T2D is a bihormonal disorder and hyperglycemia occurs as a
result of inappropriate secretion of both insulin and glucagon
(Unger and Cherrington, 2012). We now report that RYGB leads
to restoration of both GSIS and glucose-induced suppression of
glucagon secretion and that the effects are mediated by a
humoral factor. We also demonstrate that this humoral factor is
PYY and that it acts via Npy1r. Elevated levels of serum PYYCell Reports 15, 944–950, May 3, 2016 947
Figure 4. PYY Restores Function in GK Is-
lets and Improves Human Islet Function
(A and B) Islets from diabetic GK rats were chroni-
cally cultured in the presence (gray) or absence
(black bars) of PYY before insulin (A) and glucagon
(B) secretion were determined. Data are presented
as percentage of basal secretion (mean ± SEM as
% of content; insulin: PYY: 0.075 ± 0.015; without
PYY: 0.139 ± 0.022; glucagon: PYY: 1.422 ± 0.271;
without PYY: 1.443 ± 0.321; n = 5–9 experiments).
yp < 0.05 versus 1mMglucose with PYY, #p < 0.05,
##p < 0.01 for indicated comparisons.
(C) mRNA expression of the b-cell transcription
factor, Pdx1 was determined post-culture with
PYY in islets of diabetic GK rats. Data are pre-
sented as mean ± SEM, *p < 0.05.
(D and E) Insulin (D) and glucagon (E) secretion
from human islets chronically cultured with 100 pM
PYY (gray), 100 nM PYY (white), or in the absence
of PYY (black bars). Data are presented as the
percentage of that secreted at 1 mM glucose
(mean ± SEM as percentage of content; insulin:
100 pM PYY: 0.063 ± 0.004; 100 nM PYY: 0.119 ±
0.018; control: 0.19 ± 0.036; glucagon: 100 pM
PYY: 3.023 ± 0.429; 100 nM PYY: 4.137 ± 0.848;
control: 1.178 ± 0.189 (n = 14–17 and 17–29 ex-
periments respectively; five or six separate do-
nors). *p < 0.05 versus 1 mM glucose without PYY,
yyp < 0.01, yyyp < 0.001 versus 1 mM glucose with
100 pM PYY. ǂp < 0.05, ǂǂp < 0.01 versus 1 mM
glucose with 100 nM PYY. #p < 0.05, ##p < 0.01 for
indicated comparisons.following bariatric surgery has been documented (Chan et al.,
2006), but whether this translates into improved islet function
has not been studied previously. Our results are consistent
with the report that RYGB fails to improve glucose tolerance
in PYY-deficient mice (Chandarana et al., 2013). Moreover,
PYY ablation has been reported to cause gross impairment of
pancreatic b cell structure and function (Sam et al., 2012). Our
findings of elevated Pdx1 expression level in PYY-treated dia-
betic islets and increased insulin-positive cells following RYGB
suggest that PYY may be important in the restoration of b cell
functional identity.
Improved islet function following PYY pre-treatment in human
islets suggests that it is possible to extend our observations in
diabetic rats to man. In humans, circulating PYY occurs in the
range of 60 to 100 pM and close to 500 pM in some tissues
(Adrian et al., 1985). Our results indicate that PYY is effective
in vitro at both physiological (100 pM) and pharmacological
(100 nM) concentrations. Acutely administered PYY infusion in
obese, healthy volunteers has no effect on plasma insulin (Tan
et al., 2014). However, it should be noted that PYY does not
affect GSIS when applied acutely but that chronic exposure of
islets to PYY restores normal glucose regulation of insulin and
glucagon secretion. This time frame is broadly consistent with
the beneficial effect of RYGB on glucose homeostasis observed
clinically (Buchwald et al., 2004). Chronic administration of PYY
to diabetic rats has been shown to result in improved glycemic
control (Pittner et al., 2004), but the effects on pancreatic hor-
mone release were not explored. This study demonstrates that948 Cell Reports 15, 944–950, May 3, 2016within 10–14 days of RYGB surgery, pancreatic islet structure
and function in diabetic GK rats are significantly improved.
Further studies are warranted to address whether these benefi-
cial changes are sustained over the long term.
Modulation of incretin secretion (for example GLP-1) by bacte-
rial metabolites has been reported (Chimerel et al., 2014). It is
therefore likely that changes in gut microbiome following
RYGB (Tremaroli et al., 2015) also affect PYY release, which,
like GLP-1, is secreted by the entero-endocrine L-cells. A phar-
macological agent stimulating PYY production and/or mimicking




Adult male Wistar and GK rats (Taconic) were used. Rats were kept in
Makrolon Type-4 individually ventilated cages with free access to tap water
and standard rat pellet food (RM1 811004). Animals were divided into RYGB
or sham-operation group. Age- and sex-matched animals were used as con-
trols. Body weight was recorded daily during the first week after surgery and
then weekly throughout the experiments. Experiments were approved by the
Norwegian National Animal Research Authority.
Roux-en-Y Gastric Bypass Model
Animals were operated under anesthesia (isoflurane, 4% for induction and 2%
for maintenance). The surgery was performed through a small midline abdom-
inal incision. The intestine was transected 10 cm distal to the ligament of Treitz,
creating a distal and a proximal end. The proximal end was anastomosed
to the intestine, 15 cm distal to where it was previously transected. A gastric
pouch was created (2%–3% of total stomach), and the distal end of the intes-
tine was anastomosed to it in an end-to-side fashion (Kodama et al., 2013). For
sham operation, the animals were opened through a midline incision and the
viscera were gently manipulated.
Measurements of Plasma Concentrations of PYY and GLP-1
Blood was drawn from the abdominal aorta at sacrifice under ad-libitum
feeding conditions and processed as described previously (Jørgensen et al.,
2013). Plasma was kept at 80C until determination of hormones. Total
PYY was measured by radioimmunoassay (Millipore). Total GLP-1 was as-
sayed using the highly sensitive total GLP-1 (v2) kit (K150JVC-1, Mesoscale
Discovery).
Islet Isolation
Animals were used for experiments 10–14 days following surgery. All ex-
periments were conducted in accordance with the UK Animals Scientific
Procedures Act (1986). Rat islets were isolated by collagenase type V
(Sigma-Aldrich) digestion as described previously (Zhang et al., 2013).
Human pancreases were obtained with ethical approval and clinical
consent from nondiabetic donors. Islets were isolated in the Diabetes
Research & Wellness Foundation Human Islet Isolation Facility by collage-
nase digestion (Serva) using modified versions of published protocols
(Lake et al., 1989). Experiments were performed using islets from five or
six separate donors with the following parameters: mean ± SEM; age:
41.7 ± 3.7 years; BMI: 25.8 ± 1.6; islet purity: 66.3% ± 5.5%; islet viability:
77% ± 5.2%.
Secretion Studies
Islets were used for secretion studies within 2 hr of isolation. Experiments were
set with 13–15 hand-picked and size-matched islets per tube (in triplicate).
Islets were pre-incubated in Krebs-Ringer buffer (KRB) containing 2 mg/ml
BSA and 3 mmol/l glucose for 1 hr at 37C, followed by another hour of test
incubation in KRB supplemented with glucose as indicated. Insulin measure-
ments were performed at 20 mM glucose, but in some cases, to maximize
glucagon inhibition from the same islets, stimulated secretion was performed
at 6 mM glucose (Ramracheya et al., 2010). Insulin and glucagon content was
determined by radioimmunoassay (Millipore). To allow comparison of experi-
ments, secretion data are presented as mean percent basal, where basal is
secretion at 1mM glucose.
Serum and Chronic PYY Exposure Studies
Serum samples from sham-operated and RYGB GK and Wistar rat models
were used. Islets were pre-cultured for 48–60 hr in RPMI (5 mM glucose)
with the addition of 20% pooled serum or PYY (1–36) or PYY (3–36) (100 pM
or 100 nM, Bachem). Both PYY analogs produced the same effects. To explore
the role of PYY and GLP-1, anti-PYY antibody (AB22663, Abcam) or BIBP-
3226 (1 mM; Tocris) and exendin (9–39) (1 mM; Bachem) were co-applied
with the sera or PYY treatment respectively, for 48–60 hr.
Histology
Pancreases from Wistar (n = 3), sham-operated GK (n = 4), and RYGB GK
rats (n = 3) (10–14 days post-surgery) were fixed in 4% formalin, paraffin
embedded, and cut into 5-mm sections. Following dewaxing and rehydration,
endogenous peroxidase activity was blocked using 0.3% H2O2. Sections
were incubated overnight at 4C with either mouse anti-glucagon (1:500,
Sigma), guinea pig anti-insulin (1:500, in-house), or rabbit anti-somatostatin
(1:500, Santa Cruz) and visualized with 3,30-diaminobenzidine tetrahydro-
chloride (DAB) (SigmaFast, Sigma-Aldrich). Imaging for morphometric anal-
ysis was performed on images using an Axio Vision Imaging System (Zeiss).
Shape factor analysis was derived from the area and perimeter of each indi-
vidual islet (4 3 area 3 p/perimeter^ 2), with a perfect circle having a shape
factor of 1.
Statistical Methods
Statistical analyses were performed using Excel. All data are presented
as mean ± SEM. Statistical significance was evaluated by Student’s t test or
ANOVA analysis. A p value of less than 0.05 was considered significant.SUPPLEMENTAL INFORMATION
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and four figures and can be found with this article online at http://dx.doi.org/
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